June 17–18 | Shanghai
Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, has been invited to attend the Morgan Stanley China Biopharma Symposium 2026 in Shanghai on June 18. He will deliver a speech during the morning session from 10:00 to 10:50 AM at the "AI-Driven Drug Discovery in China: Accelerating from Hit to Clinic" Forum.
Dr. Alex will deconstruct in depth the critical path of AI-driven R&D bridging the gap from "technological disruption" to "clinical validation." Drawing on the latest global industry practices, he will directly address the underlying challenges and breakthrough opportunities of AI in target identification, molecular generation, clinical translation, and end-to-end cost reduction and efficiency enhancement.
As an AI-native biotechnology company, Insilico is redefining the efficiency of preclinical drug development through its advanced AI and automation platform, setting a new standard for the industry. While traditional early-stage drug discovery typically takes 2.5 to 4 years, Insilico has consistently reached preclinical candidate (PCC) nomination in an average of just 12 to 18 months, with only 60 to 200 molecules synthesized and tested per program. Since 2021, the company has nominated 31 PCCs, 13 of which have received IND approval or clearance.
While expanding the practical applications of its technology in drug discovery and life science research, Insilico is also continuously enhancing the performance of its AI platform. Drawing on extensive experience and datasets from its training platform, the company has distilled thousands of benchmarks and integrated them into MMAI Gym. Serving as both a “trainer and benchmark” for scientific AI, MMAI Gym enables organizations to train models for domain-specific reasoning while rigorously evaluating their performance on real-world tasks, advancing the path toward pharma superintelligence. To date, Human Longevity and Liquid AI have collaborated with Insilico, joining as partners of MMAI Gym.
About the Morgan Stanley China Biopharma Symposium 2026
The symposium will bring together top executives from multinational pharmaceutical companies, founders of pioneering domestic Chinese biotech firms, scholars from leading scientific research institutions, and veteran global healthcare investors. Together, we will explore the internationalization pathways of China's original therapies in cutting-edge fields such as oncology, immunology, and metabolic diseases within the current geopolitical and macroeconomic climate. The event will also delve into new paradigms for cross-border licensing deals and multinational M&As, as well as the practical implementation of AI technology in driving down costs and boosting efficiency. Morgan Stanley is committed to building an international platform that integrates efficient clinical development planning, breakthroughs in regulatory pathways, and strategic capital matchmaking, to jointly witness the next golden decade of Chinese biopharma innovation going global.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com